Top Price Market
  • Business
  • Politics
  • Investing
  • World
  • Business
  • Politics
  • Investing
  • World

Top Price Market

Investing

RAD 202 receives approval to start Phase 1 therapeutic trial

by December 20, 2024
December 20, 2024
RAD 202 receives approval to start Phase 1 therapeutic trial

Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial

Download the PDF here.

This post appeared first on investingnews.com
0
FacebookTwitterGoogle +Pinterest
previous post
House vote imminent on Trump-backed bill to avoid government shutdown
next post
Malls are using new restaurants to draw consumers as shopping centers reinvent themselves

You may also like

Trailbreaker Resources Extends Surficial Gold Signature at Golden...

Canada Gears Up for Trump Tariff Retaliation, Critical...

Energy Fuels Releases Q2 Results, Plans to Boost...

International Lithium Corp. to Receive CAD$2.2m plus a...

FDA Fast Track Designation for Narmafotinib in Advanced...

NVIDIA Q2 Stock Earnings: What Investors Need to...

Lithium Universe LtdPartners with Quebec Chemical Logistics Supply...

Sage Potash Closes Private Placement

Top 5 Canadian Mining Stocks This Week: Gold...

ChemX Receives $661,890 R&D Refund

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest

    • Nuvau Minerals Inc. Announces Grant of Options

    • Top 4 Vanadium-producing Countries

    • State Dept says DOGE’s changes will be permanent amid Musk’s departure

    • Nvidia results spark global chip rally

    • Pinnacle Silver and Gold Corp. Announces Participation in THE Mining Investment Event, Quebec City, June 3-5, 2025

    Categories

    • Business (1,670)
    • Investing (4,975)
    • Politics (7,834)
    • Uncategorized (2)
    • World (6,338)
    • About us
    • Contacts
    • Privacy Policy
    • Terms & Conditions
    • Email Whitelisting

    Disclaimer: toppricemarket.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 toppricemarket.com | All Rights Reserved


    Back To Top